MTOPS
Dr John McConnell presented the eagerly awaited first report of the Medical Therapy of Prostatic Symptoms (MTOPS) Study. The primary objective of MTOPS was to determine whether medical therapy prevents or delays the clinical progression of BPH as defined by one of the following:
acute urinary retention (AUR) renal insufficiency due to BPH recurrent urinary tract infection (UTI) or urosepsis incontinence > 4 point rise in baseline AUA symptom score (AUA-SS) confirmed within 2 -4 weeks.
Secondary research objectives included:
assess the natural history of BPH in a well-defined cohort assess changes over time in AUA-SS, Impact Index, QoL, MOS SF-36 assess changes over time in Qmax.
Additional research questions were the need for BPHrelated invasive therapy and the correlation of clinical progression with biologic progression through the study of tissue biomarkers.
The study was a double-blind, placebo-controlled, multi-centre, randomized trial, involving the randomization of 3047 men with BPH to one of the following arms: placebo, doxazosin (4 -8 mg), finasteride (5 mg) and the combination of doxazosin and finasteride. The primary outcome was time to clinical progression of the disease and minimum follow-up was 4 years (average 5 years). Baseline patient characteristics included the following mean values: symptom score 17.0 (range 12.0 -21.0), Qmax 10.6 (range 8.5 -12.3) ml/sec and prostate size 31 (range 33.0 -43.8) cc.
Of the men included in the study, 350 went on to have a BPH progression endpoint, as defined above. The distribution of all BPH progression events across all groups was: > 4 point AUA rise: 78% AUR: 12% incontinence: 9% UTI/sepsis: 1% renal insufficiency: 0%. Doxazosin and finasteride produced an equivalent but significant reduction in the cumulative incidence of BPH progression, while combination therapy was substantially more effective than either monotherapy. The actual numbers of events per group is shown in Table 1 .
Overall, 2.5% of patients developed AUR over the 5 years of follow-up. Finasteride and combination therapy were equally effective in reducing the cumulative incidence of AUR; overall risk reduction was 70 -80%. Doxazosin postponed the time to occurrence of AUR; however, over the course of the trial there was no reduction in risk of AUR. Finasteride and the combination arms also produced significant reductions in the incidence of invasive therapy. Doxazosin produced a delay in the occurrence of such procedures, but did not reduce the overall rate and was equivalent to placebo at the end of the study.
Although doxazosin and finasteride significantly improved AUA-SS and Qmax, combination therapy was clearly more effective in the long-term. Prostate volume increased in both the placebo and doxazosin arms by an average of 4.5% per year, while the finasteride and combination arms experienced a reduction in prostate volume of 13 -16%.
The adverse events (AEs) reported in the study were virtually identical to those previously reported in other medical therapy studies in BPH. The incidence of the 10 most common AEs per 100 patient years of follow-up (PYR-FU) is shown in Table 2 . Asthenia, dizziness and orthostatic hypotension were most common for doxazosin; sexual dysfunction was most common for finasteride.
Although MTOPS was not planned or actually powered to detect a reduction in the incidence of prostate cancer, there was a trend towards a lower incidence in the finasteride group, but not in the combination group. The investigators believe that this is not clinically significant.
Dr McConnell concluded that in selected patients, combination therapy was the most effective form of BPH medical therapy to improve AUA-SS and Qmax and to reduce the risk of clinical progression.
New management strategy for BPH Dr S Diamond (Philadelphia, USA) presented a poster on a novel medical management strategy for men with enlarged prostates and lower urinary tract symptoms (LUTS). This involves combination therapy with an Suggestions, comments and news can be sent to: christinemckillop@dial.pipex.com a 1 blocker plus finasteride in the short-term followed by removal of the a 1 blocker and continuation of finasteride monotherapy. A prospective study of 120 patients with a prostate size > 40 g, AUA score > 17, and urinary flow rate < 15 ml/sec was conducted, with patients doubleblinded to two groups: Group 1 -tamsulosin and finasteride and Group 2 -tamsulosin and placebo. Groups were then randomized to tamsulosin discontinuation at 6, 9, and 12 months. Patients were re-evaluated 1 month after discontinuation to determine whether they reported any change in symptoms.
At 6 months, 55% of Group 1 patients reported no change in symptom scores after discontinuing tamsulosin. These patients maintained an increase of 2.5 ml/sec in flow rate and a symptom reduction of 3 points. Of the 45% of patients in Group 1 who reported worsening symptoms after discontinuation of tamsulosin, an increase in flow rate of 1 ml/sec and no change in AUA score was reported. In Group 2, only 20% of patients were satisfied with discontinuation of tamsulosin and continuation of placebo at 6 months; 80% reported worsening symptoms. In these, a 3 ml/sec decrease in flow rate and a 3.5 point increase in AUA score was recorded.
At 9 months, 80% of Group 1 patients were successfully able to stop tamsulosin therapy. This group had an increase in flow rate of 2.7 ml/sec, and an AUA symptom reduction of 3.2 points. At 9 months, 25% of Group 2 patients were successfully discontinued and 75% reported worsening symptoms. Of the patients who reported worsening symptoms, AUA score increased by 4 points and flow rate decreased by 3 ml/sec. At 12 months, 85% of patients in Group 1 successfully discontinued tamsulosin compared with 20% in Group 2. It was concluded that patients who discontinued tamsulosin with only a placebo generally reported worsening symptoms. Finasteride can maintain the subjective and objective effects of patients with enlarged prostates and LUTS on a 1 blockers after 9 -12 months of combination therapy.
Prostate cancer markers: what's new?
Dr Bill Catalona (USA) presented a state of the art lecture overviewing the current status of markers of prostate cancer. There is a 35 -40% cancer detection rate in the PSA range 4 -10 ng/ml and attempts to improve this have been made using PSA velocity, PSA density, agespecific reference ranges and percent free PSA (fPSA). For example, a 25% fPSA value is associated with a 95% detection rate and avoidance of 20% of unnecessary biopsies.
HK2 is a new marker that converts proPSA to active PSA; higher levels are found in prostate cancer than in BPH. The ratio of HK2 to percent fPSA increases the distinction between the two diseases. HK2 is also used in predicting tumour stage and the amount of Gleason score 4 -5 in the tumour. Pro-PSA is of use in diagnosing early prostate cancer and can distinguish BPH in the range 2 -5.4 ng/ml better than percent fPSA; in the range 4 -10 ng/ml it is equivalent to percent fPSA.
The most commonly used cut-off for prostate cancer is PSA 4 ng/ml, but in the range 2.5 -3.0 ng/ml, 22 -25% of cases will have prostate cancer on initial biopsy. A low PSA at diagnosis will identify organ-confined disease with improved progression-free survival at 5 years.
The current PSA screening interval recommended by the American Urological Association and the American Cancer Society is yearly. Screening intervals of 2 or 4 years have been suggested with the argument of cost used and only a small percentage of cancers having rapid progression. However, for those that do progress rapidly, a long screening interval is a disadvantage.
Gene expression profiling has been studied and hepsin identified as being overexpressed in prostate cancer. This protease is present on the cell surface of prostate cancer cells and is involved in proliferation. One strategy would be to knock out the enzyme. AMACR is another gene associated with prostate cancer that can be identified on biopsy. HPCZ/ELAC2 are prostate cancer susceptibility genes and polymorphisms of these genes are thought to increase the risk of disease, but the data are conflicting. RNAse L is associated with hereditary prostate cancer with decreased activity of the gene product increasing the risk.
Past, present and future perspectives of surgical management of carcinoma of the prostate Dr Patrick Walsh (US) gave an overview of surgery for prostate cancer from both the urologist's and the patient's viewpoints. Quality of life following radical prostatectomy is variable and there is also wide variability in the rates of potency and continence. Continence rates as high as 95% and potency of 66 -86% have been reported from experienced centres, although these can be as low as 50% and 11%, respectively. Post-operative complications are reduced significantly if the procedure is performed in a high volume hospital by a surgeon with great experience. Definitions of cancer failure with radiotherapy are usually based on the ASTRO criteria, ie three consecutive rises in PSA following therapy. For surgery, the criteria of success is a PSA < 0.2 ng/ml. If the ASTRO criteria are applied to patients treated with surgery, much higher success rates would be reported. Dr Walsh suggested that patients treated with brachytherapy are low-risk (PSA < 10 ng/ml; Gleason score 6; T1 -T2a) and it would take years to detect failure in this group using the ASTRO criteria. Data on a large patient series from Johns Hopkins on radical prostatectomy indicate that 98.6% of patients have a PSA < 0.5 ng/ml at 10 years. Data from Seattle on brachytherapy indicate that only 60% have a PSA level < 0.5 ng/ml at 10 years. However, it is stated that 89% of patients who undergo brachytherapy at Seattle are cured using the ASTRO criteria. This a major issue from the viewpoint of the patient, who is seeking cure from his therapy.
The demands from treatment have increased with time and patients now expect no or minimal side-effects. Careful selection for surgery is needed, ie those who are likely to be cured and will sustain the fewest side-effects. Broad application of quality of life surveys is needed in order that the consequences of surgery can be determined on an individual basis. Further reductions in morbidity, improvements in surgical technique (including laparoscopy) and nerve preservation are needed in the future. Comparative trials of surgery vs other treatments should be conducted.
Implications of positive surgical margins following radical retropubic prostatectomy
Dr Alan Partin (US) discussed the role of radical prostatectomy and the consequences of positive surgical margins following surgery. Radical prostatectomy is a widely accepted treatment option for prostate cancer. In 1995, 35% of men elected to have this procedure and it is currently the primary treatment modality in prostate cancer.
A positive margin can be defined as the presence of tumour extending to the surface of the prostate. Pathologists consider that if a tumour is more than 0.1 mm away from the surface of the prostate then the surgical margin is negative. Margins most commonly occur apically and posteriorly and wide excision should be considered if positive margins are thought likely. It is important to also establish whether patients with positive margins actually had organ-confined disease prior to surgery. The presence of seminal vesicle involvement as well as the Gleason score can impact on outcome in patients with positive surgical margins. It is important to note that a positive margin alone is not necessarily a bad outcome. The incidence of positive margins at Johns Hopkins has been greatly reduced between 1984 and 2002 (40% vs < 5%) with better surgical technique. Neoadjuvant androgen therapy can reduce positive margins in 50% of patients; however, there is no consensus on the value of adjuvant therapy, such as external beam radiotherapy. Variable data have been produced with adjuvant therapy and no study has shown an overall survival benefit in men with positive margins.
Alternative treatment of BPH
Professor Roger Kirby (UK) presented a comprehensive review of the available alternative treatments to the standard therapies for BPH. The market for homeopathic medicines in general is large, with an estimated US$ 10 billion spent on dietary supplements each year in the USA. Phytotherapy using plant extracts appeals to patients as it is seen as 'natural' and holistic, with fewer side-effects than proprietary medicines. Such products are also available without the requirement to visit a physician. Professor Kirby noted that a range of beneficial effects including anti-inflammatory actions, effects on cholesterol metabolism and even inhibition of 5á reductase have been claimed for some phytotherapy products. The most notable studies of these products are:
A 6 month study of the beta stitosterol preparation (Harzol 1 ) in 200 BPH patients showed a significant decrease in IPSS scores and improved urinary flow rate vs placebo. (Berges et al, Lancet 1995; 345: 1529) . However, these benefits have not been confirmed in other well controlled studies. A study of the use of an extract from the African Dwarf Palm, Pygeum africanum, did show a 40% improvement in IPSS scores, but there was no clear overall efficacy signal for the product in this trial. A 6 month comparative trial of Permixon 1 (an extract from the Saw Palmetto plant) and finasteride showed a broadly equivalent effect (Carraro et al, Prostate 1996; 29) . A meta-analysis of 11 randomised, controlled trials showed that placebo improved Qmax values in BPH patients by a mean of 0.5 ml/sec and that Permixon 1 had an additional effect to improve peak urinary flow by a mean of 2.20 ml/sec. (Boyle et al, Urology 2000; 55: 533).
Professor Kirby summarized the evidence supporting the use of phytotherapy products by noting the scarcity of data from properly controlled, randomized trials. Those studies that have been conducted have also tended to involve small numbers of patients, be of short duration, and have usually not assessed side-effects objectively.
Alternative interventional treatment modality approaches are 'high-tech', well marketed and are claimed to be minimally invasive. One of these newer approaches is laser prostatectomy, which has been compared with standard transurethral resection of the prostate (TURP) in a study by Anson et al (Urology 1995; 46: 305 -310) . A total of 151 patients with symptomatic BPH were randomized to receive either laser prostatectomy (n ¼ 76) or TURP (n ¼ 75) and of these, 137 patients completed 1 year of follow-up. Although an improvement in symptom scores was seen with laser treatment, better results were obtained with TURP. The incidence of treatment failures was 6.5% for laser treatment compared with 0% for TURP. The incidence of haemorrhage was low in laser-treated patients (< 2%); however, there were higher rates of urinary tract infection and dysuria compared with TURP.
New test for identifying more aggressive prostate tumours
Professor Akhouri Sinha and colleagues from the University of Minnesota have recently published their results on markers that might identify more aggressive prostate cancers (Cancer 2002; 94: 3141 -3149) . Currently, the Gleason grading system is used to grade a patient's disease, with lower to higher scores indicating progression of prostate cancer. However, biologically aggressive disease cannot be distinguished within a single Gleason score. The work published examines molecular markers within an individual Gleason score in order to identify subpopulations (or clones) of aggressive prostate cancers.
Tissue samples were collected from 97 patients with prostate cancer and eight with BPH and stained with hematoxylin and eosin for pathological diagnosis. Adjacent sections were stained for the immunohistochemical localization of mouse or rabbit anti-cathepsin B (CB) antibody IgG and mouse antoihuman stefin (cystatin) A IgG. Data were also collected on patient age, race, extraprostatic extension, margin status, seminal vesicle and lymph node invasion, clinical stage at prostatectomy and mortality/survival.
Results indicated that CB and stefin A identified aggressive and less aggressive clones of prostate cancer within an individual Gleason score. Tumours with a Gleason score of 6 that were similar histologically and morphologically were heterogeneous with respect to the ratios of CB to stefin A (CB > stefin A, CB ¼ stefin A, and CB < stefin A). A significant positive association was identified between the ratio of CB and stefin A (CB > stefin A) and the incidence of pelvic lymph node metastases. Data also suggested that mortality rate increased with an increased ratio of CB to stefin A. The authors conclude that the ratio of CB to stefin A can be used in differential diagnosis and treatment of patients with prostate cancer.
Aspirin may reduce the risk of prostate cancer
Research from the Mayo Clinic, USA suggests that aspirin and other common painkillers may reduce the risk of prostate cancer. A study conducted in Minnesota randomized 1362 white men to aspirin/ibuprofen intake or not. Results showed that 4% of those who took the drugs developed prostate cancer compared with 9% of those who did not. The older the patient the more pronounced the protective effect of the drugs. The health benefit of the non-steroidal anti-inflammatory drugs (NSAIDs) has previously been demonstrated and daily intake of aspirin is recommended for prevention of cardiac arrest and stroke. Increasing evidence also suggests that NSAIDs have a protective effect against cancer of the oesophagus, bladder, breast and bowel.
The recommendation for people to take NSAID for cancer prevention is not likely at present as this would lead to an increase in side-effects such as gastro-intestinal haemorrhage, which can be life-threatening for some users. Nevertheless, between 5 and 8 million people in the UK take prescribed NSAID painkillers, including ibuprofen, naproxen and diclofenac, usually to combat arthritis. Up to 2 million people in the UK also take overthe-counter NSAIDs such as aspirin or Nurofen on a regular basis.
Donor stem cells used to attack prostate cancer
Delegates at the recent European Haematology Association congress in Florence heard that prostate cancer patients might benefit from stem cells donated by a sibling. Dr Ulf-Henrik Mellqvist of the University of Gothenberg, Sweden treated a patient with prostate cancer metastases to multiple sites with injected stem cells from a sister, who was an ideal match. The patient was also given immunosuppressants to prevent rejection. Follow-up of the patient indicated complete regression of the tumour in the nodes and stabilization of other sites, and a sharp reduction in PSA level. It was suggested that the stem cells are able to recognize the prostate cancer cells as foreign and so attack them. Dr Mellqvist pointed out that it was likely that such an expensive and radical treatment would be reserved for patients with advanced cancer.
New prostate cancer marker
A new prostate cancer marker, NMP48, is being developed that can identify 98% of cancers. NMP48 is a protein produced only by prostate cancer cells. It is expected that the new test will be marketed by Matritech in the UK within the next year. A DIY version is also expected to be launched to allow men to conduct home testing.
